Bullish Chart Formation for Agios Pharmaceuticals Inc (AGIO) After Forming Bullish Wedge Up

September 17, 2017 - By Louis Casey

Investors sentiment decreased to 1.1 in 2016 Q4. Its down 0.62, from 1.72 in 2016Q3. It dived, as 23 investors sold Agios Pharmaceuticals Inc shares while 45 reduced holdings. 19 funds opened positions while 56 raised stakes. 37.23 million shares or 3.48% more from 35.97 million shares in 2016Q3 were reported.
Employees Retirement Association Of Colorado invested in 6,194 shares. Metropolitan Life New York has 0% invested in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Bancshares Of Ny Mellon owns 128,006 shares. Moreover, Price T Rowe Inc Md has 0.01% invested in Agios Pharmaceuticals Inc (NASDAQ:AGIO) for 1.29 million shares. Moreover, Creative Planning has 0% invested in Agios Pharmaceuticals Inc (NASDAQ:AGIO) for 14,954 shares. Tiaa Cref Invest Mngmt Limited Company reported 93,697 shares. Jennison Assocs Ltd Liability Corporation invested 0.01% of its portfolio in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Fiera Corp invested in 57,615 shares or 0.01% of the stock. Marshall Wace Llp holds 30,528 shares. Moreover, Zurcher Kantonalbank (Zurich Cantonalbank) has 0% invested in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Ubs Asset Mgmt Americas has invested 0% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Profund Advsrs Limited Liability has invested 0.03% in Agios Pharmaceuticals Inc (NASDAQ:AGIO). Moreover, Eaton Vance Management has 0.01% invested in Agios Pharmaceuticals Inc (NASDAQ:AGIO) for 54,880 shares. Platinum Inv Limited holds 0.04% or 35,800 shares in its portfolio. Allianz Asset Management Ag has 11,074 shares.

Since March 20, 2017, it had 0 insider buys, and 7 selling transactions for $906,379 activity. Schenkein David P also sold $175,860 worth of Agios Pharmaceuticals Inc (NASDAQ:AGIO) shares. Biller Scott sold 6,438 shares worth $354,090.

The stock of Agios Pharmaceuticals Inc (AGIO) formed an up wedge with $71.74 target or 8.00 % above today’s $66.43 share price. The 5 months wedge indicates low risk for the $3.21B company. If the $71.74 price target is reached, the company will be worth $256.80 million more.
Rising wedges, especially for downward breakouts are tricky moments to trade. Investors must be aware that the break even failure rate for up or down breakouts is: 8% and 24%. The average rise is 28% and the decline is 14%. Wedges has high throwback and pullback rate: 73%, 63% and the percent of wedges meeting target is not more than 50%.

The stock increased 1.28% or $0.84 on September 15, reaching $66.43. About 863,491 shares traded or 99.81% up from the average. Agios Pharmaceuticals Inc (NASDAQ:AGIO) has risen 8.52% since September 17, 2016 and is uptrending. It has underperformed by 8.18% the S&P500.

Analysts expect Agios Pharmaceuticals Inc (NASDAQ:AGIO) to report $-1.74 EPS on November, 2.They anticipate $0.11 EPS change or 6.75 % from last quarter’s $-1.63 EPS. After having $-1.78 EPS previously, Agios Pharmaceuticals Inc’s analysts see -2.25 % EPS growth.

Agios Pharmaceuticals Inc (NASDAQ:AGIO) Ratings Coverage

Among 15 analysts covering Agios Pharmaceuticals (NASDAQ:AGIO), 11 have Buy rating, 0 Sell and 4 Hold. Therefore 73% are positive. Agios Pharmaceuticals had 35 analyst reports since July 23, 2015 according to SRatingsIntel. As per Monday, June 26, the company rating was downgraded by Janney Capital. The firm has “Buy” rating by Needham given on Monday, October 24. Leerink Swann upgraded the shares of AGIO in report on Wednesday, August 2 to “Outperform” rating. The firm earned “Outperform” rating on Thursday, January 21 by Credit Suisse. The company was maintained on Tuesday, August 8 by Oppenheimer. The company was maintained on Thursday, June 1 by Oppenheimer. On Tuesday, August 1 the stock rating was maintained by Oppenheimer with “Buy”. The stock of Agios Pharmaceuticals Inc (NASDAQ:AGIO) earned “Neutral” rating by TH Capital on Monday, November 9. As per Sunday, June 11, the company rating was maintained by Oppenheimer. The company was maintained on Tuesday, August 8 by Cowen & Co.

More news for Agios Pharmaceuticals Inc (NASDAQ:AGIO) were recently published by: Seekingalpha.com, which released: “Agios: Smooth First Mover In Cancer Metabolism” on August 08, 2017. Seekingalpha.com‘s article titled: “Agios, Amigos!” and published on May 26, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.